Home NTLA
57.02
  Price9.15%   -5.67
 
loading
Sep-22-22 05:49AM Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just BoughtThe Motley Fool
Sep-21-22 10:04AM Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022Benzinga
Sep-20-22 05:55AM Cathie Wood Is Loading Up on These 3 Stocks: Should You?The Motley Fool
Sep-19-22 05:35AM "The Era of the Gene-Edited Human Is Here"The Motley Fool
12:15PM Intellia (NTLA) Reports Positive Results for CRISPR CandidatesZacks Investment Research
Sep-19-22 12:06PM SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To KnowBenzinga
10:15AM 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 YearsThe Motley Fool
Sep-19-22 10:02AM What 4 Analyst Ratings Have To Say About Intellia TherapeuticsBenzinga
07:19AM This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedExBenzinga
Sep-16-22 07:15AM Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisGlobeNewswire Inc.
07:00AM Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)GlobeNewswire Inc.
Sep-01-22 10:33AM Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022Benzinga
09:18AM Expert Ratings for Intellia TherapeuticsBenzinga
Sep-01-22 09:13AM Where Intellia Therapeutics Stands With AnalystsBenzinga
Aug-24-22 05:56AM Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From YesterdayBenzinga
05:19AM Macy's, Palo Alto Networks And Other Big Gainers From TuesdayBenzinga
Aug-23-22 09:59AM Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin SymposiumGlobeNewswire Inc.
Aug-05-22 11:09AM Expert Ratings for Intellia TherapeuticsBenzinga
Aug-04-22 02:02AM Clorox, Crocs And Some Other Big Stocks Moving Lower On ThursdayBenzinga
01:43AM Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues BeatZacks Investment Research
Aug-04-22 11:31AM Why Intellia Therapeutics Stock Is Sinking TodayThe Motley Fool
08:45AM Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research
Aug-04-22 07:30AM Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc.
Jun-06-22 12:49PM Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2022 UpdateSeeking Alpha
May-24-22 05:39AM Analyst Ratings for Intellia TherapeuticsBenzinga
May-18-22 12:51PM The Correction In Biopharmaceutical Stocks Is Likely OverSeeking Alpha
May-13-22 11:52AM Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool
May-09-22 08:47AM 10 Biggest Price Target Changes For MondayBenzinga
May-06-22 03:02AM Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues BeatZacks Investment Research
May-05-22 08:55AM Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
08:43AM The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder StudyBenzinga
May-04-22 03:19AM Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & MoreZacks Investment Research
May-02-22 07:30AM Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering ConferenceGlobeNewswire Inc.
Apr-28-22 10:09AM Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022Benzinga
09:15AM 4 Analysts Have This to Say About Intellia TherapeuticsBenzinga
Apr-28-22 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company UpdatesGlobeNewswire Inc.
Apr-20-22 07:40AM 3 Top Biotech Stocks Ready for a Bull RunThe Motley Fool
Apr-19-22 06:20AM 3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool
Apr-13-22 10:45AM CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool
Apr-11-22 10:12AM Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?Zacks Investment Research
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):